


Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (currently amended) A method of treating, ~~preventing, modifying or managing complex regional pain syndrome~~, which comprises administering to a patient ~~having complex regional pain syndrome in need of such treatment, prevention, modification or management a therapeutically or prophylactically effective amount of a selective cytokine inhibitory drug~~ a therapeutically effective amount of (+)-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione} of the formula,



or a pharmaceutically acceptable salt; or solvate; ~~or stereoisomer~~ thereof.

2. (currently amended) The method of claim 1, which further comprises administering to the patient a therapeutically ~~or prophylactically~~ effective amount of at least one second active agent.

3. (original) The method of claim 2, wherein the second active agent is capable of relieving or reducing pain.

4. (original) The method of claim 2, wherein the second active agent is an antidepressant, antihypertensive, anxiolytic, calcium channel blocker, alpha-adrenergic receptor agonist, alpha-adrenergic receptor antagonist, ketamine, anesthetic, muscle relaxant, non-narcotic analgesic, opioid analgesic, anti-inflammatory agent, immunomodulatory agent, immunosuppressive agent, corticosteroid, anticonvulsant, cox-2 inhibitor, hyperbaric oxygen, or a combination thereof.


5. (original) The method of claim 2, wherein the second active agent is salicylic acid acetate, celecoxib, ketamine, gabapentin, carbamazepine, oxcarbazepine, phenytoin, sodium valproate, prednisone, nifedipine, clonidine, oxycodone, meperidine, morphine sulfate, hydromorphone, fentanyl, acetaminophen, ibuprofen, naproxen sodium, griseofulvin, amitriptyline, imipramine or doxepin.

6 to 8. canceled.

9. (currently amended) The method of claim 1 8, wherein the complex regional pain syndrome is type I or type II.

10 to 22. canceled.

23. (currently amended) A method of treating, ~~preventing, modifying or managing complex regional pain syndrome~~, which comprises administering to a patient ~~having complex regional pain syndrome in need of such treatment, prevention, modification or management a therapeutically or prophylactically effective amount of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof~~, before, during or after surgery, psychological or physical therapy directed at reducing or avoiding a symptom of pain in the patient, a therapeutically effective amount of (+)-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonyl-ethyl]-4-acetylaminoisindoline-1,3-dione} of the formula,



or a pharmaceutically acceptable salt or solvate thereof.

24 to 26. canceled.

27. (currently amended) The method of claim 1 ~~or 8~~, wherein the ~~selective cytokine inhibitory drug~~ compound is (+)-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione}.

28. (new) The method of claim 1, wherein the compound is a pharmaceutically acceptable salt.

29. (new) The method of claim 1, wherein the compound is a pharmaceutically acceptable solvate.

30. (new) The method of claim 1, wherein the compound is administered orally.

31. (new) The method of claim 1, wherein the compound is administered in the form of a tablet or capsule.

32. (new) The method of claim 1, wherein the compound is administered in an amount of about 1 to about 1,000 mg per day.

33. (new) The method of claim 1, wherein the compound is administered in an amount of about 5 to about 500 mg per day.

34. (new) The method of claim 1, wherein the compound is administered in an amount of about 10 to about 200 mg per day.